Candida krusei is a yeast-like fungus that causes serious bloodstream infections primarily in people with weakened immune systems, and it stands apart from most other Candida species because it is inherently resistant to fluconazole, the most widely prescribed antifungal drug in hospitals worldwide. That built-in resistance is not something the organism picks up from drug exposure; it is hardwired into the shape of the protein that fluconazole is designed to attack. The story gets more interesting when you learn that this same organism has a second life under a different name, fermenting chocolate and pickled vegetables in kitchens around the world.
One Organism With Two Names
In clinical settings, doctors and lab reports call this fungus Candida krusei. In food science and industrial microbiology, the same organism goes by Pichia kudriavzevii. For years, researchers treated these as separate species, but genomic comparisons have settled the question: the two names describe one organism, with genomes that are 99.6% identical in DNA sequence.1PLOS Pathogens. Population genomics shows no distinction between pathogenic Candida krusei and environmental Pichia kudriavzevii: One species, four names The name that sticks depends on the context. Medical journals overwhelmingly use C. krusei, while food technologists prefer P. kudriavzevii. In fermented foods, this yeast is actually useful: it contributes to cocoa bean fermentation, where inoculating it alongside other yeasts can shorten fermentation time and improve the chemical profile of the finished chocolate.2PubMed. Chemical implications and time reduction of on-farm cocoa fermentation by Saccharomyces cerevisiae and Pichia kudriavzevii The dual identity matters because it means C. krusei is not purely a hospital organism. It thrives in nature, in food, and in the human gut, and understanding its ecology helps explain how it ends up causing infections in vulnerable patients.
Why Fluconazole Does Not Work
Most Candida infections are treated with fluconazole because it is cheap, well-tolerated, and effective against the most common species. Fluconazole works by binding to a protein called Erg11, which the fungus needs to build its cell membrane. Block Erg11, and the membrane falls apart. In C. krusei, however, Erg11 has a slightly different structure that gives fluconazole a naturally poor grip on the protein. The drug simply does not latch on tightly enough to do its job.3Open Forum Infectious Diseases. Genomic Insights of Candida krusei, an Emerging Fungal Pathogen With Intrinsic Antifungal Resistance
That weak binding alone would be enough to make fluconazole unreliable, but C. krusei adds a second layer of defense. It constitutively produces an efflux pump called Abc1p, a molecular doorman that actively pushes azole drugs back out of the cell. Even when small amounts of fluconazole manage to get inside, the pump ejects them before they can accumulate to a damaging concentration. Researchers showed this by using chemical inhibitors to block the pump: once Abc1p was silenced, C. krusei became significantly more sensitive to azole drugs.4PubMed Central. Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei The combination of a poor drug target and an always-on ejection system is what makes fluconazole resistance intrinsic to C. krusei rather than something it develops over time.
Who Is at Risk
C. krusei infections are not random. They cluster in specific patient populations: people with blood cancers, organ transplant recipients, premature infants in intensive care, and anyone whose white blood cells have been knocked out by chemotherapy. The common thread is severe immune suppression, and particularly neutropenia, the dangerous drop in neutrophils that follows aggressive cancer treatment. In one study of patients who died from C. krusei bloodstream infections, nearly 80% had remained neutropenic throughout.5JAMA Internal Medicine. Candida krusei Fungemia: An Escalating Serious Infection in Immunocompromised Patients
There is also a strong selection effect from fluconazole itself. In hospitals that use fluconazole heavily for prevention or treatment of other fungal infections, C. krusei has room to flourish precisely because its competitors are being killed off. Studies have found a strong statistical association between prior fluconazole exposure and subsequent C. krusei infection, and genetic analysis showed this was not person-to-person spread but rather selection pressure giving the resistant organism an open niche.6PubMed. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use At the individual level, fluconazole prophylaxis selects for non-albicans Candida species with reduced susceptibility, including C. krusei and C. glabrata.7Journal of Antimicrobial Chemotherapy. Effect of fluconazole consumption on long-term trends in candidal ecology In practical terms, this means the very drug hospitals rely on to prevent fungal infections can inadvertently set the stage for one of the hardest-to-treat species to emerge.
Outbreaks in pediatric wards illustrate how dangerous C. krusei can become in vulnerable populations. A prolonged outbreak in one hospital’s neonatal unit revealed that the organism was spreading from environmental sources, including healthcare workers’ hands and washbasins. The pediatric group was disproportionately affected, with C. krusei isolated from the blood of a much larger fraction of children than adults.8PubMed Central. Prolonged Outbreak of Candida krusei Candidemia in Paediatric Ward of Tertiary Care Hospital Yet cross-transmission is not always the story. In a hematology unit cluster, genetic analysis of isolates showed that most patients carried their own distinct strains, suggesting they were already colonized and that the infection emerged from their own gut flora under immune suppression.9PubMed Central. A cluster of Candida krusei infections in a haematological unit
How Dangerous the Infections Are
C. krusei bloodstream infections carry a grim prognosis. In one case-control study, only about a third of patients with C. krusei bloodstream infection survived to hospital discharge, compared to nearly nine in ten matched controls. For roughly half of those who died, the C. krusei infection was judged to be the direct cause of death.10PubMed. Risk factors and outcomes of Candida krusei bloodstream infection: a matched, case-control study Crude mortality in another analysis reached above 85%, though after adjusting for the severity of the patients’ underlying illness, researchers found that much of that excess risk came from the fact that C. krusei tends to strike the sickest patients, those with blood cancers, persistent neutropenia, and heavy corticosteroid use.11Open Forum Infectious Diseases. Risk Factors and Mortality Associated with Candida krusei Bloodstream Infections In other words, C. krusei does not necessarily kill more aggressively than other Candida species once you account for how sick the patients already are, but it selects for the most vulnerable hosts and then limits the drugs available to treat them.
How C. krusei Survives Inside the Body
Beyond drug resistance, C. krusei has evolved ways to dodge and manipulate the immune system. Macrophages, the white blood cells responsible for engulfing and destroying pathogens, struggle with this organism. In laboratory experiments, C. krusei managed to survive inside macrophages by interfering with the normal process cells use to digest engulfed invaders. After being swallowed by a macrophage, C. krusei was able to prevent the compartment it was trapped in from maturing into an acidic, destructive environment. In some cases, the yeast cells began to grow filaments inside the macrophage and eventually burst the cell open entirely.12PubMed Central. The interaction between Candida krusei and murine macrophages results in multiple outcomes, including intracellular survival and escape from killing
C. krusei also triggers an unusually strong inflammatory response from human immune cells. When researchers compared how macrophages reacted to several different Candida species, C. krusei provoked the most dramatic changes in immune signaling, an overreaction that can itself contribute to tissue damage during an infection.13PubMed Central. Differential recognition of Candida tropicalis, Candida guilliermondii, Candida krusei, and Candida auris by human innate immune cells On top of these immune evasion tactics, a large proportion of C. krusei isolates from patients produce enzymes that actively break down host tissue. In isolates collected from HIV-infected patients, more than half were classified as strong producers of both phospholipase and proteinase, enzymes that chew through cell membranes and proteins, respectively.14PubMed Central. Antifungal Resistance Profile, Biofilm Formation, and Virulence Factor Production in Candida krusei Isolates From HIV-Infected Patients in Cameroon C. krusei can also form biofilms on surfaces like medical devices, which makes the organism harder to clear once it has colonized a catheter or other implanted hardware.
What Drugs Actually Work
Because fluconazole is off the table from the start, clinicians treating C. krusei infections turn to a different set of antifungal drugs. The echinocandins, a class that includes caspofungin, micafungin, and anidulafungin, are typically the first choice. These drugs work by a completely different mechanism from azoles: they block synthesis of a sugar polymer called glucan that forms the scaffolding of the fungal cell wall. C. krusei is generally susceptible to echinocandins, and most guidelines recommend them as first-line therapy for invasive C. krusei infections.
Amphotericin B, an older and more toxic antifungal, remains effective against most C. krusei strains and is used when echinocandins are not an option or when the infection has spread to the brain, where echinocandins do not penetrate well. Among the newer azoles, voriconazole retains meaningful activity against C. krusei because it binds to the Erg11 protein more tightly than fluconazole does. In animal models of disseminated C. krusei infection, voriconazole significantly reduced fungal burden in the kidneys, and isavuconazole performed comparably while also reducing the organism’s presence in the brain, something fluconazole could not achieve.15PubMed Central. Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei So while fluconazole fails, clinical alternatives do exist. The concern is what happens when those alternatives begin to fail as well.
When Backup Drugs Start to Lose Ground
The fact that C. krusei is intrinsically resistant to only one antifungal class, the older azoles, might seem manageable. The real worry is acquired resistance, the organism developing new defenses against the drugs that currently work. This is already happening on multiple fronts.
For the broader azoles, C. krusei can develop resistance to voriconazole through the same efflux pump that underlies its fluconazole resistance. In both patients and laboratory experiments, strains exposed to voriconazole over time showed increasing expression of the Abc1p pump gene. Blocking the pump with a chemical inhibitor restored voriconazole sensitivity in these resistant strains, confirming the pump was the primary escape route.16PubMed Central. In vivo and in vitro acquisition of resistance to voriconazole by Candida krusei In a broader international survey of C. krusei isolates, overexpression of the Abc1p gene was identified as the major mechanism behind acquired azole resistance.17PubMed Central. Prevalence of Antifungal Resistance, Genetic Basis of Acquired Azole and Echinocandin Resistance, and Genotyping of Candida krusei Recovered from an International Collection
For echinocandins, the news is also sobering. Resistance in C. krusei follows the same pattern seen in other Candida species: mutations in a gene called FKS1, which encodes the drug’s target enzyme. A case report described a C. krusei strain from a patient with acute leukemia that had acquired an FKS1 mutation, altering the enzyme enough to make it less sensitive to echinocandins.18PubMed Central. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase The same international collection study confirmed that FKS1 mutations in a particular hotspot region were the dominant mechanism behind echinocandin resistance in C. krusei worldwide.17PubMed Central. Prevalence of Antifungal Resistance, Genetic Basis of Acquired Azole and Echinocandin Resistance, and Genotyping of Candida krusei Recovered from an International Collection
Even amphotericin B, the antifungal of last resort for many difficult infections, is not entirely safe from C. krusei resistance. Researchers studying amphotericin B-resistant C. krusei mutants found that resistance was linked to chemical modifications of proteins involved in the cell wall and in the pathway that produces ergosterol, the membrane component that amphotericin B targets.19PubMed Central. Post-translational modifications confer amphotericin B resistance in Candida krusei isolated from a neutropenic patient Although widespread amphotericin B resistance in C. krusei has not been reported, these findings suggest the organism has the molecular flexibility to develop it.
Identifying C. krusei in the Lab
Rapid identification matters because starting the wrong antifungal in a patient with C. krusei can cost critical time. One of the simplest tools is a chromogenic culture medium, which uses chemical dyes that react with enzymes specific to different Candida species. On CHROMagar Candida, C. krusei colonies grow with a distinctive rough, spreading appearance and a pale pink-to-purple color that distinguishes them from C. albicans (green) and C. tropicalis (blue). This medium correctly identified over 95% of C. krusei isolates in validation studies and has the added benefit of revealing mixed infections where more than one Candida species is present.20PubMed Central. Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei, and Candida (Torulopsis) glabrata More advanced methods, including DNA sequencing and mass spectrometry, are now standard in many hospitals and provide definitive identification within hours rather than days.
The Food-to-Hospital Pipeline
The fact that C. krusei is the same organism as the industrially useful P. kudriavzevii raises an uncomfortable question: are food and environmental strains a reservoir for drug-resistant infections? A recent study in China addressed this directly by comparing C. krusei isolates collected from fermented vegetables with those collected from patients in clinical settings. The results were striking. Isolates from fermented vegetables showed higher resistance to several antifungal drugs, including fluconazole, voriconazole, itraconazole, amphotericin B, and caspofungin, compared to the clinical strains. At the same time, whole-genome sequencing showed that food and clinical isolates were genetically related and spread across the same range of genetic clusters, meaning there is no neat wall between the organism living harmlessly in your pickles and the one causing bloodstream infections.21PubMed Central. Biology and genetic diversity of Candida krusei isolates from fermented vegetables and clinical samples in China
This does not mean eating fermented food causes fungal infections. In a person with a functioning immune system, swallowing C. krusei is harmless. But the finding that environmental strains carry equal or greater drug resistance than hospital strains complicates the picture. Industrial and agricultural use of antifungal chemicals could be selecting for resistant strains in the environment, and those strains could colonize the guts of people who later become immunosuppressed. The organism’s ability to occupy ecological niches from cocoa fermentation heaps to neonatal intensive care units makes it unusually versatile. Researchers studying cocoa fermentation have even begun microencapsulating P. kudriavzevii as a starter culture to standardize the fermentation process,22PubMed. Effect of microencapsulated inoculum of Pichia kudriavzevii on the fermentation and sensory quality of cacao CCN51 genotype which means deliberate propagation of this organism in food production is expanding, not contracting. Whether that deliberate cultivation could contribute to the clinical problem is an open question, and one that the medical and food science communities have only recently started discussing under the broader umbrella of “One Health” thinking about antimicrobial resistance.